JP2010526857A - ジヨードチロニンを含んでなる新規な医薬組成物及びその治療的使用 - Google Patents

ジヨードチロニンを含んでなる新規な医薬組成物及びその治療的使用 Download PDF

Info

Publication number
JP2010526857A
JP2010526857A JP2010507937A JP2010507937A JP2010526857A JP 2010526857 A JP2010526857 A JP 2010526857A JP 2010507937 A JP2010507937 A JP 2010507937A JP 2010507937 A JP2010507937 A JP 2010507937A JP 2010526857 A JP2010526857 A JP 2010526857A
Authority
JP
Japan
Prior art keywords
day
diiodothyronine
iodothyronine
active substance
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010507937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526857A5 (enExample
Inventor
レベーブ，ザビエル
タロー，ネリー
ファビエール，ローラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Santé et de la Recherche Médicale filed Critical Institut National de la Santé et de la Recherche Médicale
Publication of JP2010526857A publication Critical patent/JP2010526857A/ja
Publication of JP2010526857A5 publication Critical patent/JP2010526857A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010507937A 2007-05-16 2008-05-16 ジヨードチロニンを含んでなる新規な医薬組成物及びその治療的使用 Withdrawn JP2010526857A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290634 2007-05-16
PCT/EP2008/056074 WO2008138993A1 (en) 2007-05-16 2008-05-16 New pharmaceutical compositions comprising diiodothyronine and their therapeutic use

Publications (2)

Publication Number Publication Date
JP2010526857A true JP2010526857A (ja) 2010-08-05
JP2010526857A5 JP2010526857A5 (enExample) 2011-06-23

Family

ID=38521888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010507937A Withdrawn JP2010526857A (ja) 2007-05-16 2008-05-16 ジヨードチロニンを含んでなる新規な医薬組成物及びその治療的使用

Country Status (5)

Country Link
US (1) US20110028554A1 (enExample)
EP (1) EP2068858A1 (enExample)
JP (1) JP2010526857A (enExample)
CA (1) CA2687380A1 (enExample)
WO (1) WO2008138993A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992341A1 (en) * 2007-05-16 2008-11-19 Université Joseph Fourier New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
US20120065267A1 (en) * 2010-09-09 2012-03-15 T*Amine, Llc Compositions including 3,5-l-t2 and methods of use thereof
JP6352188B2 (ja) 2012-08-20 2018-07-04 大塚製薬株式会社 糖代謝能の測定方法及びそれに使用する組成物
KR20210014204A (ko) * 2013-03-15 2021-02-08 오츠카 세이야쿠 가부시키가이샤 지방산 연소에 의한 인슐린 저항성의 측정 방법, 및 그에 사용하는 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067247A (en) * 1958-08-19 1962-12-04 Hoechst Ag Process for preparing l(+)-3, 5-diiodothyronine
US4426453A (en) * 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
US5767227A (en) * 1989-11-03 1998-06-16 Lotus Biochemical Corp. Iodothyronine polymers
US6221911B1 (en) * 1995-06-07 2001-04-24 Karo Bio Ab Uses for thyroid hormone compounds or thyroid hormone-like compounds
US5635209A (en) * 1995-10-31 1997-06-03 Vintage Pharmaceuticals, Inc. Stabilized composition of levothyroxine sodium medication and method for its production
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.

Also Published As

Publication number Publication date
US20110028554A1 (en) 2011-02-03
EP2068858A1 (en) 2009-06-17
CA2687380A1 (en) 2008-11-20
WO2008138993A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
Hwang et al. Fructose-induced insulin resistance and hypertension in rats.
Casirola et al. α-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice
KR100533618B1 (ko) 당뇨병 치료를 위한 방법 및 조성물
Mendez et al. Regulation of hyperglycemia and dyslipidemia by exogenous L-arginine in diabetic rats
Watała et al. Anti-diabetic effects of 1-methylnicotinamide (MNA) in streptozocin-induced diabetes in rats
FR3125409A1 (fr) Complément alimentaire permettant de lutter contre l’infertilité féminine et masculine
JP2010526858A (ja) 甲状腺ホルモンを含んでなる新たな医薬組成物及びその治療的使用
Tessari Changes in protein, carbohydrate, and fat metabolism with aging: possible role of insulin
Larner D-chiro-inositol in insulin action and insulin resistance-old-fashioned biochemistry still at work.
WO2005009433A1 (en) Use of 3,5 diiodothyronine as regulators of lipid metabolism
JPS61500496A (ja) 膵臓のランゲルハンス島のインシュリン分泌を高めるためのシステイン誘導体またはその塩類の使用
US20110028554A1 (en) pharmaceutical compositions comprising diiodothyronine and their therapeutic use
Yamamoto et al. Effect of inhibition of α-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats
Zhao et al. HYPOGLYCAEMIC AND HYPOLIPIDAEMIC EFFECTS OF EMODIN AND ITS EFFECT ON L‐TYPE CALCIUM CHANNELS IN DYSLIPIDAEMIC–DIABETIC RATS
US10107795B2 (en) Composition and methods for the prevention and treatment of diet-induced obesity
Ozono et al. Dopamine D2Receptor Modulates Sodium Handling via Local Production of Dopamine in the Kidney
Hartery et al. Loss of maternal calcitriol reversibly alters early offspring growth and skeletal development in mice
RU2153878C1 (ru) Способ получения лекарственных форм изониазида, обладающих пониженной гепатотоксичностью
A Rendon The bioenergetics of isolated mitochondria from different animal models for diabetes
Weissman et al. Starvation
JP2005517716A (ja) ヒトにおける老化および老化障害の治療法および予防的治療
Becker Rapid effects of estradiol on motivated behaviors
JPWO2003068215A1 (ja) ミトコンドリア病用薬剤
Breuillé et al. Assessment of tissue glutathione status during experimental sepsis
JP2004215562A (ja) 飲食物用添加剤、医薬組成物、ｇｌｕｔ４トランスロケート剤及びトランスロケート方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110502

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121002